The Form 4 filing was filed on November 18, 2026, two days after the November 16 sale. Form 4 is an SEC report of changes in an insider's stock ownership.
The filing information also notes a Rule 10b5-1 trading plan. Such plans set trading instructions in advance. The available details do not confirm whether that plan covered this sale.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 1,000 |
| Price | $547.86 |
| Total Transaction Value | $547,860.00 |
| Insider | |
| Ticker Symbol | VRTX |
| Company | VERTEX PHARMACEUTICALS INC / MA |
| Insider Name | Thornberry Nancy |
| Insider Title | Director |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 1,109 |
| Position Size Change | 47.42% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of Vertex Pharmaceuticals (VRTX) shares by director Nancy Thornberry. The report lists one transaction with code S, the SEC code for a share sale.
What was the average price of the transaction?
The average sale price was $547.86 per share. That average applies to the 1,000 shares in the reported sale.
How did this transaction affect the insider's holdings?
The sale left Nancy Thornberry with 1,109 reported shares. She sold 1,000 shares, or 47.42% of the shares she owned before the sale.
What's the total transaction value?
The total reported transaction value was $547,860.00. That is the value of the single sale listed in this filing.
Are there any special circumstances around this transaction?
The filing information includes a Rule 10b5-1 plan notice, but its scope is unclear from the available details. Such a notice may cover the filing as a whole. No footnote text is available to confirm whether this sale was covered by the plan. The plan's start date and trading schedule are also unknown.
For research purposes only; not investment advice.